|Mr. Michel Vounatsos||CEO & Director||2.65M||N/A||1962|
|Dr. Michael D. Ehlers||Exec. VP and Head of R&D||2.1M||N/A||1969|
|Mr. Jeffrey D. Capello||Exec. VP of Fin. & CFO||N/A||N/A||1965|
|Mr. Gregory F. Covino||VP of Fin. & Chief Accounting Officer||N/A||N/A||1966|
|Mr. Mark J. Hernon||Sr. VP & Chief Information Officer||N/A||N/A||1964|
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. The company's Phase II clinical trial products comprise Opicinumab for MS; BAN2401 for Alzheimer's disease; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild AD. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Biogen Inc.’s ISS Governance QualityScore as of April 1, 2018 is 1. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 3; Compensation: 3.